Evidence Explorer / MS-N019

Evidence at a glance

• Population: People receiving acute-leukemia induction therapy or hematopoietic stem-cell transplantation.
• Intervention: Restrictive “neutropenic” or low-bacterial diets versus regular or liberalized diets using standard food-safety practices.
• Finding: Randomized trials have not shown fewer clinically important infections with the restrictive diet.
• Boundary: A liberalized diet is not permission to ignore food hygiene or an individual transplant program’s instructions.

What the human evidence found

A 2022 acute-leukemia trial randomized 200 patients: 98 to a regular diet and 102 to a neutropenic diet. Blood-culture positivity was 6 versus 9; induction mortality 9 versus 4; remission was 94% in both groups. None of the reported infection, organ-support, mortality or remission comparisons was statistically significant.

The multicenter NEUTRODIET study included more than 200 adults receiving transplantation or intensive therapy with prolonged neutropenia. Grade 2 or worse infections occurred in 61% with a nonrestrictive diet and 65% with the protective diet; the nonrestrictive strategy was noninferior and patient satisfaction was higher.

A newer randomized noninferiority report in transplant and acute-leukemia populations adds to the same direction of evidence. Registration or publication alone is not proof; the conclusion rests on reported clinical outcomes.

Limits and what this cannot establish

Diet definitions differed across centers, and these trials do not test every food, outbreak or profoundly immunocompromised situation. Some comparisons were powered for noninferiority, not superiority.

The absence of benefit from broad restrictions does not mean foodborne infection is harmless. It supports careful food safety without unnecessary exclusion when the treating program agrees.

Safety and practical context

Wash produce, avoid cross-contamination, cook high-risk animal products appropriately, follow local water and outbreak advice, and avoid foods specifically prohibited by the transplant or infectious-disease team. The exact plan may change with graft-versus-host disease, mucositis or local policy.

Funding and conflicts were not fully re-extracted for every component trial.

Questions for the care team

• Does my center require a neutropenic diet, or standard food-safety guidance?
• Which foods are restricted because of actual contamination risk rather than tradition?
• How will the plan protect nutrition and enjoyment when appetite is already poor?

Sources checked

• Acute-leukemia randomized trial (PMID 35803707)
• NEUTRODIET multicenter randomized trial (PMID 37450382)
• Liberalized versus neutropenic diet noninferiority trial (PMID 41406403)

Appraisal date: October 14, 2026. Last literature search: October 14, 2026.

Educational evidence summary, not medical advice. Research regimens describe what was studied; they are not personal prescribing instructions and should not replace cancer treatment or individualized supportive care.